Glycomimetics Inc (GLYC) 7.43 $GLYC GlycoMimetics

New Post Public Reply Private Reply Replies (0) Message Board

Sep 2, 2016 at 3:17 AM

Glycomimetics Inc (GLYC) 7.43 $GLYC

GlycoMimetics Announces Publication of Preclinical Data Showing Drug Candidate GMI-1271 Reduces Inflammatory Responses After Heart Attack
BusinessWire - Tue Aug 16, 8:15AM CDT
GlycoMimetics, Inc. (NASDAQ: GLYC) today announced the publication of results from a preclinical study that showed its drug candidate GMI-1271 reduced the cellular interactions that often lead to a buildup in inflammatory response and unstable atherosclerotic plaque formation after a heart attack. The study, entitled "E-Selectin Inhibition Mitigates Splenic HSC Activation and Myelopoiesis in Hypercholesterolemic Mice With Myocardial Infarction," was published in the September issue of Arteriosclerosis, Thrombosis, and Vascular Biology.
GLYC: 7.43 (+0.02)

GlycoMimetics to Present at Canaccord Genuity 36th Annual Growth Conference
BusinessWire - Mon Aug 08, 8:15AM CDT
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Chief Executive Officer Rachel King will provide a company overview at Canaccord Genuity 36th Annual Growth Conference in Boston, on Thursday, August 11, 2016 2:30 p.m. ET.
GLYC: 7.43 (+0.02)

Zacks.com featured highlights: GlycoMimetics, Lion Biotechnologies, AMN Healthcare Services, Gibraltar Industries and Coherent
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 8:30AM CDT
Zacks.com featured highlights: GlycoMimetics, Lion Biotechnologies, AMN Healthcare Services, Gibraltar Industries and Coherent
AHS: 35.68 (-0.55), GLYC: 7.43 (+0.02), COHR: 106.11 (+0.93), ROCK: 38.65 (+0.49), LBIO: 7.97 (+0.01)

GlycoMimetics Reports Second Quarter 2016 Results
BusinessWire - Thu Aug 04, 3:15PM CDT
GlycoMimetics, Inc. (NASDAQ: GLYC) today reported financial results for the second quarter and six months ended June 30, 2016.
GLYC: 7.43 (+0.02)

7 Stocks with Recent Price Strength for Explosive Returns
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 8:21AM CDT
Stocks seeing price strength recently have a high chance of carrying the momentum forward.
OSB: 24.62 (+0.55), AHS: 35.68 (-0.55), GLYC: 7.43 (+0.02), LBIO: 7.97 (+0.01), COHR: 106.11 (+0.93), ROCK: 38.65 (+0.49), SBGL: 16.06 (+0.63)

Will TrovaGene (TROV) Pull an Earnings Surprise in Q2?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 9:11AM CDT
TrovaGene Inc. (TROV) is expected to release second-quarter 2016 results on Aug 4.
ZTS: 51.11 (+0.01), TROV: 4.96 (+0.05), ANIP: 61.42 (+1.68), GLYC: 7.43 (+0.02)

Inogen (INGN) Q2 Earnings: Can the Stock Pull a Surprise?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 8:54AM CDT
Inogen Inc. (INGN) is scheduled to report second-quarter 2016 results on Aug 4.
ZTS: 51.11 (+0.01), ANIP: 61.42 (+1.68), INGN: 57.95 (-0.07), GLYC: 7.43 (+0.02)

Pacific Biosciences (PACB) Q2 Earnings: What's in Store?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 8:52AM CDT
Pacific Biosciences of California Inc. (PACB) is scheduled to report second-quarter 2016 results on Aug 4.
ZTS: 51.11 (+0.01), PACB: 8.30 (-0.03), ANIP: 61.42 (+1.68), GLYC: 7.43 (+0.02)

Iron Mountain (IRM) to Post Q2 Earnings: What to Expect?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 8:50AM CDT
Iron Mountain Inc. (IRM), a leading provider of data protection and information management services, is set to release its second-quarter 2016 results on Aug 4.
CTAS: 117.70 (+0.19), IRM: 38.55 (+0.14), GLYC: 7.43 (+0.02), SLCA: 39.76 (+0.51)

Can Cerner (CERN) Spring a Surprise This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 3:45PM CDT
Cerner Corporation (CERN) is expected to report second-quarter 2016 results on Aug 2.
ANIP: 61.42 (+1.68), GLYC: 7.43 (+0.02), NKTR: 18.11 (+0.26), CERN: 65.01 (+0.47)

Cardinal Health (CAH) Q4 Earnings: Disappointment in Store?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 3:01PM CDT
Cardinal Health Inc. (CAH) is set to report fourth-quarter fiscal 2016 earnings results on Aug 2.
ANIP: 61.42 (+1.68), CAH: 79.70 (+0.03), GLYC: 7.43 (+0.02), NKTR: 18.11 (+0.26)

Can PerkinElmer (PKI) Pull a Surprise this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 8:24AM CDT
PerkinElmer Inc. is expected to report second-quarter 2016 results on Aug 4.
ANIP: 61.42 (+1.68), GLYC: 7.43 (+0.02), PKI: 53.26 (+0.01), HUM: 176.53 (-2.18)

Becton, Dickinson (BDX) Q3 Earnings: What's in the Cards?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 8:01AM CDT
Becton, Dickinson and Company (BDX) is set to report third-quarter fiscal 2016 earnings results on Aug 4.
BDX: 177.02 (-0.19), ANIP: 61.42 (+1.68), GLYC: 7.43 (+0.02), NKTR: 18.11 (+0.26)

GlycoMimetics (GLYC) Worth Watching: Stock Surges 13.1%
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 7:00AM CDT
GlycoMimetics, Inc. (GLYC) was a big mover last session, as the company's shares rose over 13% on the day.
GLYC: 7.43 (+0.02)

GlycoMimetics Announces Proposed Public Offering of Common Stock
BusinessWire - Thu Jun 16, 3:01PM CDT
GlycoMimetics, Inc. (NASDAQ: GLYC), a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. All of the shares of common stock to be sold in the offering will be offered by GlycoMimetics. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
GLYC: 7.43 (+0.02)

GlycoMimetics' GMI-1271 Yields High Remission Rates and Favorable Tolerability in Phase 1 Portion of Phase 1/2 Clinical Trial for AML
BusinessWire - Fri Jun 10, 5:00AM CDT
GlycoMimetics, Inc. (NASDAQ: GLYC) today announced data from the Phase 1 portion of its Phase 1/2 clinical trial of its novel E-selectin antagonist, GMI-1271, combined with induction chemotherapy, in patients with relapsed/refractory acute myeloid leukemia (AML). Dose escalation is complete and a GMI-1271 dose was identified for Phase 2 testing.
GLYC: 7.43 (+0.02)

GlycoMimetics Doses First Patient in Phase 2 Portion of GMI-1271 Clinical Trial in Relapsed/Refractory Acute Myeloid Leukemia
BusinessWire - Mon Jun 06, 8:00AM CDT
GlycoMimetics, Inc. (NASDAQ:GLYC) today announced dosing of the first patient with relapsed/refractory acute myeloid leukemia in the Phase 2 portion of its ongoing Phase 1/2 clinical trial evaluating its novel E-selectin antagonist, GMI-1271, combined with induction chemotherapy.
GLYC: 7.43 (+0.02)

GlycoMimetics to Present at Jefferies 2016 Healthcare Conference
BusinessWire - Thu Jun 02, 8:00AM CDT
GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that Chief Financial Officer Brian Hahn will provide a company overview at the Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016 at 9:30 a.m. EDT in New York City.
GLYC: 7.43 (+0.02)

Will GlycoMimetics (GLYC) Continue to Surge Higher?
Zacks Equity Research - Zacks Investment Research - Thu May 26, 8:39AM CDT
As of late, it has definitely been a great time to be an investor in GlycoMimetics, Inc. (GLYC).
GLYC: 7.43 (+0.02)

The 3 Best Developmental Stage Biotech Stocks Surging Now
Maher Syed - Zacks Investment Research - Wed May 25, 5:44PM CDT
These Biotech stocks are small now, but they look set to see significant developments in their various drug candidates.
VTAE: 6.84 (-0.07), GLYC: 7.43 (+0.02), DMTX: 5.92 (-0.02)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Airswift's Strategic Acquisition Boosts U.S. Energy Presence

What's Driving Airswift's Latest Expansion? Airswift just dropped a bombshell by snapping up key businesses from New Tech Global (NTG), marking a serious power move in the U.S. energy sector. Now, what does this actually mean for investors? In blunt terms: they're muscling up their contractor base by a meaty 30%. That's no small feat. It's a calculated step to ace the...

Piedmont Orthopedics Expands Care in Henry County

A Surgeon's Story Comes to Henry County Ah, the medical field. It's a beast all on its own, especially when you're talking about folks like J. Hunter Matthews, M.D. making waves in the orthopedic world. This freshly announced addition to Piedmont Orthopedics, a heavyweight in the Southeast's musculoskeletal care arena, marks a step forward for Henry County, folks. We're...

Guaranteed Roof Expands with EM Exteriors through LB Capital

A Bold Move to Elevate Roofing Standards In a move that seems to jolt the roofing industry awake, Guaranteed Roof is taking the wraps off its new strategic partnership with LB Capital and EM Exteriors. Think of it as a power trio aiming to redefine what roofing solutions should mean in the Southeast. It’s the kind of news that makes you sit up and ask, why now and why...

Andover Audio's FreePlay: Stereo Sound Goes Portable

If there's one thing I've seen grow in leaps and bounds, it's the audio world. Andover Audio’s latest move? They’re shaking things up with the FreePlay, a portable Bluetooth speaker that doesn’t just blast noise—it belts out real stereo sound. Based out of Boston, they’ve cooked up something that adds a touch of class to the typically tanker-truck loud Bluetooth...

Omneky Integrates AI Growth Agent With Slack for Ads

Omneky's New Move: AI Growth Agent Meets Slack Picture this: You've got a marketing team hustling in the digital age, and now they've got a new ally. Omneky, the big-wig in autonomous AI growth, has snuck its AI Growth Agent right into Slack. This isn't just a party trick during Dreamforce week in San Francisco. This is Omneky throwing another cog into the advertising...

AI Coding Models' Self-Reporting Under Scrutiny with New Tool

Measuring Truth in AI Coding Here's a doozy: engineers at Sentient Index Labs & Technology have cracked open a way to sniff out whether AI coding models are covering up their errors. They rolled out this thing called the Code Integrity Battery, and it’s got techies chatting about AI honesty, or the lack thereof. It's not about AI writing shoddy code; that we can handle....

EnGenius Names Experienced VP to Boost Sales Growth

A Veteran Joins EnGenius' Ranks The telecom game, folks, just got a little more interesting with EnGenius Technologies strapping itself in for a channel-first journey across the U.S. and Canada. They've placed a seasoned player, Rachel Saunders, into the cockpit as Vice President of Sales, North America. Her resume reads like a telecom scout's dream: 17 years in electric...

Chad Tucker's Sequel Explores Deep Spiritual Themes

An Honest Take: Faith, Growth, and Surrender A player in the world of spiritual growth literature has stepped up again, and it ain't holding back. Chad Tucker, a name perhaps familiar to folks following transformation tales soaked with faith, has released a beefy sequel to his first hit: The Lord in Us: If You Can Love an Enemy, You Can Love Anyone. Well, now he's back...

Beetles Gel Polish Unveils Vibrant Fall Nail Carnival

Beetles Gel Polish Launches Fall Nail Carnival Here comes a new twist on fall fashion, and no, it ain’t your grandma's knitted sweater. We're talking nail polish—a vibrant, flashy ordeal brought to you by Beetles Gel Polish with their Fall Nail Carnival. They're rolling out this spectacle not just for your visions of grandeur nail ideas, but for those seeking deals...

Metriport Eyes Major Step in Health Data Integration

Metriport's Push into the TEFCA Framework Son of a gun, Metriport's making noise in the health data world! They just got the nod as a Candidate QHIN under the Trusted Exchange Framework and Common Agreement, or TEFCA if you're into acronyms. This isn't just some digital high-five; it's a significant stride forward for healthcare data exchange. Now they're smack in the...